Stein M B, Black B, Brown T M, Uhde T W
Section on Anxiety and Affective Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892.
Biol Psychiatry. 1993;33(8-9):647-50. doi: 10.1016/0006-3223(93)90105-m.
We administered dipyridamole, an adenosine reuptake inhibitor, to 12 outpatients with DSM-III-R anxiety disorders (2 patients with generalized anxiety disorder, 10 patients with panic disorder). Dipyridamole was administered at a flexible dose in a single-blinded fashion following a placebo washout phase and elimination of placebo responders. The mean duration of active treatment with dipyridamole was 46 days (range 21-88 days); the mean peak dose of dipyridamole was 202 +/- 55 mg/day (range 100-300 mg/day). Symptom ratings were completed at regular intervals by the patient and by a research nurse unaware of the treatment condition. Clinically significant improvement in anxiety symptoms was not demonstrated. The implications of these findings for an adenosinergic dysfunction model of panic disorder are discussed.
我们对12名符合《精神疾病诊断与统计手册第三版修订本》（DSM-III-R）焦虑症诊断标准的门诊患者（2例广泛性焦虑症患者，10例惊恐障碍患者）给予双嘧达莫（一种腺苷再摄取抑制剂）治疗。在经过安慰剂洗脱期并排除安慰剂反应者后，以单盲方式灵活给药双嘧达莫。双嘧达莫的平均有效治疗时长为46天（范围为21 - 88天）；双嘧达莫的平均峰值剂量为202±55毫克/天（范围为100 - 300毫克/天）。患者和一名不知治疗情况的研究护士定期完成症状评分。未显示出焦虑症状有临床上显著的改善。本文讨论了这些发现对惊恐障碍的腺苷能功能障碍模型的意义。
